BioCentury
ARTICLE | Clinical News

Secnidazole: Completed Phase III enrollment

September 7, 2015 7:00 AM UTC

Symbiomix completed enrollment of 189 patients in a double-blind, placebo-controlled, U.S. Phase III trial evaluating a single dose of 2 g oral SYM-1219. FDA also granted Fast Track designation to SYM...